Studying Gene Expression in Samples From Patients With Rhabdoid Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01553175
First received: March 10, 2012
Last updated: March 17, 2012
Last verified: March 2012
  Purpose

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.


Condition Intervention
Brain and Central Nervous System Tumors
Kidney Cancer
Genetic: DNA analysis
Genetic: gene expression analysis
Genetic: mutation analysis
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

Study Type: Observational
Official Title: Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Absence or presence BRG1 and BRM expression in rhabdoid tumors [ Designated as safety issue: No ]
  • Mechanism of suppression of BRG1 and BRM genes [ Designated as safety issue: No ]

Estimated Enrollment: 25
Study Start Date: March 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
  • To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
  • To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.
  • To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.
  • To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.

OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Tumor samples from patients diagnosed with rhabdoid tumors
  • Matched frozen tumor tissue from BRG1-negative tumors (preferred) or matched genomic DNA from tumors, 100 ng per tumor from BRG1-negative tumors
  • Any source of DNA from BRG1-negative tumors (tumors, blood, etc.)
  • Matched frozen tumor tissue from BRM-negative tumors to confirm that BRM is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01553175

Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: David Reisman, MD, PhD University of Florida
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01553175     History of Changes
Other Study ID Numbers: CDR0000728521, COG-AREN12B5
Study First Received: March 10, 2012
Last Updated: March 17, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
childhood atypical teratoid/rhabdoid tumor
rhabdoid tumor of the kidney

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Central Nervous System Neoplasms
Kidney Neoplasms
Neoplasms
Nervous System Neoplasms
Rhabdoid Tumor
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Glandular and Epithelial
Nervous System Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms

ClinicalTrials.gov processed this record on October 22, 2014